The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model

Blood Coagulation and Fibrinolysis

Volumn 23, Issue 5, 2012, Pages 370-378

  Shenkman, Boris ^a   Livnat, Tami ^a   Lubetsky, Aharon ^a   Tamarin, Ilia ^a   Budnik, Ivan ^b   Einav, Yulia ^c   Martinowitz, Uriel ^a  

^a The Amalia Biron Research Institute of Thrombosis and Hemostasis   (Israel)

^b SARATOV STATE MEDICAL UNIVERSITY   (Russian Federation)

^c HOLON INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

factor XIII; fibrinogen; fibrinolysis; hemodilution; TAFI; tPA

Indexed keywords

BLOOD CLOTTING FACTOR 13; FIBRINOGEN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CONTROLLED STUDY; DRUG SENSITIVITY; FIBRINOLYSIS; HEMATOLOGICAL PROCEDURE; HEMODILUTION; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; ROTATION THROMBOELASTOMETRY; THROMBIN TIME;

ADULT; CARBOXYPEPTIDASE U; FACTOR XIII; FIBRINOGEN; FIBRINOLYSIS; HEMODILUTION; HUMANS; ISOTONIC SOLUTIONS; THROMBELASTOGRAPHY; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; WHOLE BLOOD COAGULATION TIME;

EID: 84863316242     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328352cb3f     Document Type: Article

References (32)

1. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33:4-15. (Pubitemid 37449290)
2. Fries D, Innerhofer P, Reif C, Streif W, Klinger A, Schobersberger W, et al. The effect of fibrinogen substitution on reversal of dilutional coagulopathy: an in vitro model. Anesth Analg 2006; 102:347-351. (Pubitemid 43152574)
3. Lorenzo C, Calatzis A, Welsch U, Heindl B. Fibrinogen concentrate reverses dilutional coagulopathy induced in vitro by saline but not by hydroxyethyl starch 6%. Anesth Analg 2006; 102:1194-1200.
4. Levrat A, Gros A, Rugeri L, Inaba K, Floccard B, Negrier C, et al. Evaluation of rotation thromboelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth 2008; 100:792-797. (Pubitemid 351774327)
5. Schols SEM, Fejge MA, Lance MD, Hamulyak K, Cate H, Hewemskerk JW, et al. Effects of plasma dilution on tissue-factor-induced thrombin generation and thromboelastograpgy: partly compensation role of platelets. Transfusion 2008; 48:384-394.
6. Bolliger D, Szlam F, Molinaro RJ, Rahe-Meyer N, Levy JH, Tanaka KA. Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. Br J Anaesth 2009; 102:793-799.
7. Gallimore MJ, Harris SL, Tappenden KA, Winter M, Jones DW. Urokinase induced fibrinolysis in thromboelastography: a model for studying fibrinolysis and coagulation in whole blood. J Thromb Haemost 2005; 3:2506-2513. (Pubitemid 41727168)
8. Nielsen VG. Hemodilution modulates the time of onset and rate of fibrinolysis in human and rabbit plasma. J Heart Lung Transplant 2006; 25:1344-1352. (Pubitemid 44696322)
9. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257:2912-2919. (Pubitemid 12118804)
10. Bolliger D, Szlam F, Levy JH, Molinaro RJ, Tanaka KA. Haemodilutioninduced profibrinolytic state is mitigated by fresh-frozen plasma: implications for early haemostatic intervention in massive haemorrhage. Br J Anaesth 2010; 104:318-325.
11. Vucellic D, Milijc P, Antonijevic N, Ilicevic M. The role of rotational thromboelastometry in real time assessment of haemostasis in surgical settings. Srp Arch Celok Lek 2010; 138 (SUPPL. 1):43-49.
12. Fenger-Eriksen C, Anker-Moller E, Heslop J, Ingerslev J, Sorensen B. Thromboelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate. Br J Anaesth 2005; 94:324-329. (Pubitemid 40352852)
13. Haas T, Fries D, Velik-Salchner C, Reif C, Klinger A, Innerhofer P. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution. Anesth Analg 2008; 106:1360-1365. (Pubitemid 351571061)
14. Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ, Ingerslev J, Sorensen B. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth 2008; 101:769-773.
15. Rahe-Meyer N, Solomon C, Winterhalter M, Piepenbrock S, Tanaka K, Haverich A, et al. Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurism surgery. J Thorac Cardiovasc Surg 2009; 138:694-702.
16. Solomon C, Pichlmaier U, Schoechl H, Hagi C, Raymondos K, Schneinichen, et al. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth 2010; 104:555-562.
17. Waydhas C, Görlinger K. Coagulation management in multiple trauma. Unfallchirung 2009; 112:942-950; (in German).
18. Muszbek L, Bagoly Z, Bereczky Z, Katona E. The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. Cardiovasc Hematol Agents Med Chem 2008; 6:190-205.
19. Mosesson MW, Siebenlist KR, Hernandez I, Lee KN, Christiansen VJ, McKee PA. Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation. J Thromb Haemost 2008; 6:1565-1570.
20. Gerlach R, Tolle F, Raabe A, Zimmermann M, Siegemund A, Seiferi V. Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased FXIII activity. Stroke 2003; 23: 1618-1623.
21. Ternström L, Radulovic V, Karlsson M, Baghaei F, Hyllner M, Bylock A, et al. Plasma activity of individual coagulation factors, hemodilution and blood loss after cardiac surgery: a prospective observational study. Thromb Res 2010; 126:128-133.
22. Bajzar L, Nesheim M, Morser J, Tracy PB. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273:2792-2798. (Pubitemid 28133926)
23. Wang W, Roffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273:27176-27181. (Pubitemid 28500426)
24. Schneider M, Nesheim M. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis. J Biol Chem 2004; 279:13333-13339. (Pubitemid 38468855)
25. Petroianu GA, Liu J, Maleck WH, Mattinger C, Bergler WF. The effect of in vitro hemodilution with gelatin, dextran, hydroxyethyl starch or Ringer's solution on thromboelastograph. Anesth Analg 2000; 90:795-800. (Pubitemid 30190780)
26. Schols SEM, Lance MD, FeijgeMAH, Damoiseaux J, Marcus MA, Hamulyak K, et al. Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery. Thromb Haemost 2010; 103:318-328.
27. Fries D, Krismer A, Klinger A, Streif W, Klima G, Wenzel V, et al. Effect of fibrinogen on reversal of dilutional coagulopathy: a porcine model. Br J Anaesth 2005; 95:172-177. (Pubitemid 41487140)
28. Walker JB, Bajzar L. Complete inhibition of fibrinolysis by sustained carboxypeptidase B activity: the role and requirement of plasmin inhibitors. J Thromb Haemost 2007; 5:1257-1264. (Pubitemid 46902129)
29. Schramko AA, Kuitunen AH, Suojaranta-Yinen RT, Niemi TT. Role of fibrinogen-, factor VIII-and XIII-mediated clot propagation in gelatinhaemodilution. Acta Anaesth Scand 2009; 53:731-735.
30. Theusinger OM, Bauling W, Asmis LM, Seifert B, Spahn DR. In vitro factor XIII SUPPL.ementation increases clot firmness in Rotation Thromboelastometry (ROTEM). Thromb Haemost 2010; 104:385-391.
31. Rijken DC, Lijnen HR. New insights into the molecular mechanism of the fibrinolytic system. J Thromb Haemost 2009; 7:4-13.
32. Weisel JW. Structure of fibrin: impact on clot stability. J Thromb Hemost 2007; 5 (SUPPL.1):116-124. (Pubitemid 46958824)